Table 2. Summary of publications investigating EGFR and PIK3CA mutations in pancreatic adenocarcinoma.
| # | Author | Year | No. of patients | EGFR mutations | EGFR mutation type | PIK3CA mutations | Response to inhibitor | Origin |
|---|---|---|---|---|---|---|---|---|
| 1 | Samuels et al. (21) | 2004 | 11 | ND | ND | 0/11 (0%) | ND | U.S. |
| 2 | Kwak et al. (24) | 2006 | 55 | 2/55 (3.6%) | Exon 19 Deletion | ND | 2/2 disease stabilization | U.S. |
| 3 | Immervoll et al. (25) | 2006 | 43 | 0/43 (0%) | ND | ND | Norway | |
| 4 | Tzeng et al. (26) | 2007 | 31 | 0/31 (0%)* | ND | ND | U.S. | |
| 5 | Lee et al. (27) | 2007 | 66 | 1/66 (1.5%) | Exon 20 Substitution (2453G>A, C818Y) | ND | ND | Korea |
| 6 | Willmore-Payne et al. (28) | 2007 | 12 | 0/12 (0%)** | ND | ND | U.S. | |
| 7 | Morinaga et al. (29) | 2008 | 42 | 0/42 (0%) | ND | ND | Japan | |
| 8 | Jimeno et al. (30) | 2008 | 10 | 0/10 (0%) | 1/10 (10%) | 1/1 Sensitive | U.S./ Europe | |
| 9 | Iyer et al. (31) | 2008 | 27 | 0/27 (0%) | 0/27 (0%) | ND | U.S. | |
| 10 | Ueno et al. (32) | 2009 | 31 | 0/31 (0%) | ND | ND | Japan | |
| 11 | Dewald et al. (33) | 2009 | 5 | 1/5 (20%) | Gain ~4n | ND | ND | U.S. |
| 12 | Janku et al. (34) | 2010 | 8 | ND | ND | 1/8 (12.5%) | NA | U.S. |
| 13 | Lozano-Leon et al. (35) | 2011 | 34 | 3/34 (8.8%) | R841R, T571T, R831C | ND | As wild-type | Spain |
| TOTAL | 7/347 (2%) | 2/56 (3.6%) |
ND, not done; NA, not available. *Tzeng et al. found EGFR mutations in 26/31 (83.8%) samples, yet all were silent mutations. 25 patients had 2361G>A in exon 20, and one patient had 2508C>T in exon 21. **Willmore-Payne et al. found no activation mutations. our samples had polymorphism in exon 20